Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUNE: Durvalumab plus tremelimumab in advanced neuroendocrine neoplasms
2016-002858-20Phase 2Active
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Dec 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in apudoma (NET), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Clinical Benefit Rate by RECIST v1.1 at month 9. Started Dec 2016; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2016-002858-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002858-20.